Bristol-Myers Squibb (BMY) Revenue — Quarter Ended Jun 30, 2025
Total revenue for the quarter was essentially flat compared to the same period last year, but showed a sequential increase from the preceding quarter. The company's net product sales remained stable year over year, while alliance and other revenues contributed to the overall revenue mix.
Key takeaway
Quarter ended Jun 30, 2025 · FY2025 Q2
Total revenue for the quarter was essentially flat compared to the same period last year, but showed a sequential increase from the preceding quarter. The company's net product sales remained stable year over year, while alliance and other revenues contributed to the overall revenue mix.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$12.3B
Revenue reported for this quarter.
Quarter-over-quarter
+9.5%
Change from the immediately preceding quarter.
Year-over-year
+0.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$47.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2024 | $11.9B | +8.4% |
| Dec 31, 2024 | $12.3B | +7.5% |
| Mar 31, 2025 | $11.2B | -5.6% |
| Jun 30, 2025 | $12.3B | +0.6% |
Revenue performance
Revenue increased compared to the immediately preceding quarter, reversing the prior sequential decline. The year-over-year comparison shows minimal change, indicating a stabilization in top-line performance.
Quarterly comparison
Compared to the prior quarter, revenue rose, driven by higher net product sales and alliance revenue. Versus the same quarter a year ago, total revenue was nearly unchanged, with a slight increase in alliance revenue offsetting a minor decline in net product sales.
What to watch
Monitor the trajectory of net product sales and alliance revenue in upcoming quarters for signs of sustained growth or further stabilization.